All In Biotech

Free tool

FAERS Monitor: Phyrago

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 216099 or its brand name (Phyrago, Dasatinib). Reports on generic versions are filed under their own applications.

Reports

9,294

Serious

8,481

91% of reports

Hospitalization

2,857

Death reported

1,354

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • pleural effusion1,211
  • drug ineffective728
  • drug intolerance575
  • drug resistance538
  • death470
  • diarrhoea441
  • thrombocytopenia430
  • dyspnoea416
  • malignant neoplasm progression399
  • fatigue384
  • nausea374
  • pyrexia373
  • off label use367
  • hepatotoxicity336
  • rash334

Reports by year received

View as table
YearReports
200640
2007106
2008113
2009162
2010158
201194
2012244
2013221
2014372
2015324
2016428
2017538
2018647
2019767
2020706
20211,046
2022541
2023566
2024797
2025821
2026603

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,044,865 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
drug resistanceSignal53848.444.524,430
pleural effusionSignal1,21145.943.552,270
hepatotoxicitySignal33634.731.210,796
drug intoleranceSignal57513.512.56,659
malignant neoplasm progressionSignal3998.88.02,772
thrombocytopeniaSignal4308.78.02,941
pyrexiaSignal3732.42.2321
rash3341.71.6105
dyspnoea4161.71.5112
diarrhoea4411.51.487
drug ineffective7281.31.239
death4701.21.122
fatigue3841.11.05
nausea3741.11.02
off label use3670.90.91

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.